Neon raises $70M in series B

Neoantigen vaccine play Neon Therapeutics Inc. (Cambridge, Mass.) raised $70 million in a series B round led by new investor Partner Fund Management. New investors Fidelity, Wellington Management, Inbio Ventures and Nextech Invest also participated, as did existing investors Third Rock Ventures and Access Industries.

The company's lead program, personalized neoantigen vaccine NEO-PV-01, is in a Phase Ib trial in combination with anti-PD-1 mAb Opdivo nivolumab to treat patients with melanoma, non-small cell lung cancer (NSCLC) or bladder cancer. Bristol-Myers Squibb Co. (NYSE:BMY) markets Opdivo...